FINWIRES · TerminalLIVE
FINWIRES

Repligen Likely to Benefit From Diverse Growth Factors, RBC Says

By

Repligen (RGEN) is expected to benefit from diverse growth drivers in a strengthening bioprocessing market, RBC Capital Markets said in a Thursday note.

"Bioprocessing demand trends are the most robust in Tools, and Repligen is a pure play," the note said.

The report also pointed to growth prospects at its commercial products, biosimilars, product replacement cycles, and a strategy

reboot in China.

The note said the growth drivers should enable the firm to return to mid-teens organic sales growth, as RBC resumes coverage of Repligen with an outperform rating and a $160 price target.

"The growth pressures associated with a specific gene therapy customer should lap next year, while several tailwinds...should ramp," the report said.

Price: $105.97, Change: $+2.59, Percent Change: +2.50%

Related Articles

Australia

Update: Federal Reserve Terminates Enforcement Actions With UBS, Credit Suisse

(Updates with UBS' response to a request for comment.)The Federal Reserve said Friday it has terminated its enforcement actions with UBS Group (UBS), Credit Suisse and their subsidiaries.UBS declined to comment to.Price: $45.46, Change: $-0.89, Percent Change: -1.92%

$UBS
Australia

Illumina's Mid-Teens Clinical Growth Appears Sustainable Over Next 1 to 2 Years, RBC Says

Illumina's (ILMN) mid-teens clinical growth appears sustainable over the next one to two years, driven largely by oncology testing and screening applications, as the company sees building clinical momentum and fading competitive concerns, RBC said in a Thursday note.With clinical markets now comprising over 50% of the company's sales, growth has accelerated to 20% in each of the past two quarters, supported by robust growth forecasts for Illumina's oncology customers, according to the note.Illumina sees fading competitive concerns with Roche's Axelios 1 sequencing update seeing mixed response, RBC said, adding that it did not see any updates at Roche's investor event earlier this week to change the narrative.Additionally, RBC said that the weakness Illumina is seeing in academic demand is an industry-wide problem and that several new product launches should enable demand to at least flatten by next year, which will be enough to meet or exceed Wall Street forecasts.RBC has an outperform rating on the company, with a $170 price target.Price: $139.93, Change: $-3.31, Percent Change: -2.31%

$ILMN
Australia

Gray Media, E.W. Scripps Complete Swap of Five TV Stations

Gray Media (GTN) and E.W. Scripps (SSP) closed their swap of television stations across five markets in four US states, the companies said Friday.The cash-free, even exchange, announced in July, includes stations in Lansing, Michigan; Lafayette, Louisiana; Colorado Springs and Grand Junction in Colorado; and Twin Falls, Idaho.Shares of Gray Media fell 1.2% in Friday trading, and E.W. Scripps dropped 2.3%.Price: $4.12, Change: $-0.05, Percent Change: -1.20%

$GTN$SSP